EBAMed is awarded EUR 2.4 million to develop its cardiac motion management product for the non-invasive treatment of heart arrhythmias

EBAMed was a Venture Kick winner and a Venture Leaders Life Sciences in 2018 and was one of the TOP 100 Swiss startups in 2019. The Geneva-based medtech startup develops a non-invasive medical device for heart arrhythmia treatment, which can be integrated into any existing radiation therapy machine and enables physicians to monitor heart movements automatically and in real-time. Its cardiac motion management product facilitates an out-patient procedure, as it does not require any hospitalization or sedation.

“The procedure is quick, safe, painless and suitable for any age and health condition patient with no side-effects, and we expect it will provide an efficient alternative to existing treatments,” states EBAMed’s co-founder, Prof. Ugo Amaldi (CERN). “EBAMed will work with several clinical institutions, such as the National Center of Oncological Hadron therapy CNAO in Italy and the University Hospital UZ Leuven in Belgium, in order to fine-tune the use of its technology.”

Heart arrhythmia is a major worldwide public health problem, accounting for 15–20% of all deaths. It affects over 15 million people in Europe and North America, and this number is expected to double in the next 50 years due to the aging population and lifestyle changes. Currently, catheter ablation is the gold standard for arrhythmia treatment. This is a staff-intensive invasive procedure requiring patient hospitalization and comes with a high risk of complications, such as bleeding, infection, and damage to heart valves and blood vessels. EBAMed’s solution should ensure a more accurate, effective, and safe treatment with its non-invasive medical device for heart arrhythmia treatment using proton therapy.

The Horizon2020 EIC pilot aims to support top-class innovators, startups, small companies, and researchers with bright ideas that are radically different from existing products, services, or business models, that are highly risky, and that have the potential to scale up internationally. The program will provide a total amount of around EUR 3 billion throughout 2018-2020 to fund the most talented innovators and help their companies scale up and expand beyond European borders.